Pharmaceutical

BeiGene's Q1 2025 Financial report Market Trend Financial statements BeiGene BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
Novo Nordisk's Q1 2025 Financial report Market Trend Financial statements Novo Nordisk Novo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.
Meloxicam vs Ibuprofen Comparison Meloxicam Ibuprofen Meloxicam vs Ibuprofen: Meloxicam is a long-acting NSAID used for managing osteoarthritis and rheumatoid arthritis pain, while Ibuprofen provides quick relief for pain, inflammation, and fever. Learn which medication is best for your needs.
Noromectin vs Ivermectin Ivermectin Comparison Noromectin vs Ivermectin are both antiparasitic drugs, but Noromectin is a brand name for ivermectin used primarily in veterinary medicine. While both treat similar parasitic infections, Noromectin is specifically formulated for animals, whereas ivermectin can be used for humans and animals.
Finasteride vs Minoxidil Finasteride Minoxidil Comparison Finasteride vs Minoxidil both treat hair loss but work differently. Finasteride blocks the hormone responsible for hair thinning, while Minoxidil stimulates hair growth directly. Each has its benefits depending on individual needs and the cause of hair loss.
FDA Drug Rejections (January-April 2025) FDA From January to April 2025, the FDA rejected six new drug applications, citing issues like clinical data, CMC problems, and third-party manufacturing concerns. Learn more about each case.
Pfizer's Q1 2025 Financial report Market Trend Financial statements Pfizer Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
Eli Lilly's Q1 2025 Financial report Market Trend Financial statements Eli Lilly Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
AstraZeneca's Q1 2025 Financial report Market Trend Financial statements AstraZeneca AstraZeneca's Q1 2025 revenue rose 10% to $13.59B, with strong growth in oncology and China contributing $1.8B. CEO highlights rich pipeline, U.S. expansion, and 2030 $80B revenue goal.
Novartis's Q1 2025 Financial report Market Trend Financial statements Novartis Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.

< Pre 1...52 53 545556 57 58...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles